Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INCBMRN · Entity 2404 | EVP, Chief R&D Officer | September 30, 2026 | October 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOMARIN PHARMACEUTICAL INC
Report date September 30, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 47,732 |
Reported balance
After 2026-09-30 transaction · row 1
1 source rowRow 1 · 2026-09-30 · Tax withholding · Disposed 4,086 · Balance 47,732 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 30, 2026 Filed Oct 2, 2026 00:23 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 4,086 | $60.00 | $245,160.00 |
DisclosureSEC source: 0001628280-26-064272 · wk-form4_1790886185.xml · nonDerivative · entry 1 Friberg Gregory R · CIK 0002038768 · EVP, Chief R&D Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,732 Read SEC document |
| May 07, 2026 Filed May 11, 2026 21:01 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 3,281 | $53.85 | $176,681.85 |
DisclosureSEC source: 0001628280-26-033639 · wk-form4_1778533271.xml · nonDerivative · entry 1 Friberg Gregory R · CIK 0002038768 · EVP, Chief R&D Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,818 Read SEC document |
| March 17, 2026 Filed Mar 18, 2026 17:39 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 1,629 | $56.05 | $91,305.45 |
DisclosureSEC source: 0001628280-26-019266 · wk-form4_1773855579.xml · nonDerivative · entry 2 Friberg Gregory R · CIK 0002038768 · EVP, Chief R&D Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,099 Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 17:39 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantStock Option (Right to Buy Common Stock) · Derivative | 45,600 | $0.00 Strike: $57.43 | $0.00 |
DisclosureSEC source: 0001628280-26-019266 · wk-form4_1773855579.xml · derivative · entry 3 Friberg Gregory R · CIK 0002038768 · EVP, Chief R&D Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,600 Underlying: Common Stock · 45,600 shares Expires 2036-03-15 F2 · derivative.exercise_date: Option grant vests 12/48th on March 16, 2027 and 1/48th on the 16th day of each month thereafter. Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 17:39 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 19,150 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-019266 · wk-form4_1773855579.xml · nonDerivative · entry 1 Friberg Gregory R · CIK 0002038768 · EVP, Chief R&D Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,728 F1 · price: Restricted stock units granted March 16, 2026. Price not applicable. Read SEC document |
| February 26, 2026 Filed Feb 27, 2026 01:39 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 6,326 | $60.38 | $381,937.31 |
DisclosureSEC source: 0001628280-26-012539 · wk-form4_1772156343.xml · nonDerivative · entry 1 Friberg Gregory R · CIK 0002038768 · EVP, Chief R&D Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,578 F1 · price: The price in column 4 is the weighted average price. The purchase price actually received ranged from $60.36 to $60.51. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price Read SEC document |
| October 31, 2025 Filed Feb 13, 2026 23:54 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 398 | $45.54 | $18,122.93 |
DisclosureSEC source: 0001628280-26-008218 · wk-form5_1771026863.xml · nonDerivative · entry 1 Friberg Gregory R · CIK 0002038768 · EVP, Chief R&D Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,904 F1 · date: Represents the shares acquired by the reporting person on October 31, 2025, pursuant to the issuer's Employee Stock Purchase Plan. Read SEC document |
| September 30, 2025 Filed Oct 2, 2025 20:33 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 3,304 | $54.16 | $178,944.64 |
DisclosureSEC source: 0002038768-25-000007 · wk-form4_1759437191.xml · nonDerivative · entry 1 Friberg Gregory R · CIK 0002038768 · EVP, Chief R&D Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,506 Read SEC document |
| March 17, 2025 Filed Mar 18, 2025 22:23 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantStock Option (Right to Buy Common Stock) · Derivative | 41,170 | $0.00 Strike: $71.55 | $0.00 |
DisclosureSEC source: 0001048477-25-000033 · wk-form4_1742336605.xml · derivative · entry 2 Friberg Gregory R · CIK 0002038768 · EVP, Chief R&D Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,170 Underlying: Common Stock · 41,170 shares Expires 2035-03-16 F2 · derivative.exercise_date: Option grant vests 12/48th on March 17, 2026 and 1/48th on the 17th day of each month thereafter. Read SEC document |
| March 17, 2025 Filed Mar 18, 2025 22:23 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 17,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001048477-25-000033 · wk-form4_1742336605.xml · nonDerivative · entry 1 Friberg Gregory R · CIK 0002038768 · EVP, Chief R&D Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,810 F1 · price: Restricted stock units granted March 17, 2025. Price not applicable. Read SEC document |
| September 30, 2024 Filed Oct 1, 2024 20:51 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantStock Option (Right to Buy Common Stock) · Derivative | 49,850 | $0.00 Strike: $70.29 | $0.00 |
DisclosureSEC source: 0001048477-24-000146 · wk-form4_1727815879.xml · derivative · entry 3 Friberg Gregory R · CIK 0002038768 · EVP, Chief R&D Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,850 Underlying: Common Stock · 49,850 shares Expires 2034-09-29 F2 · derivative.exercise_date: Option grant vests 12/48th on September 30, 2025 and 1/48th per month thereafter. Read SEC document |
| September 30, 2024 Filed Oct 1, 2024 20:51 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 7,870 | $0.00 | $0.00 |
DisclosureSEC source: 0001048477-24-000146 · wk-form4_1727815879.xml · nonDerivative · entry 2 Friberg Gregory R · CIK 0002038768 · EVP, Chief R&D Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,060 F1 · price: Restricted stock units granted on September 30, 2024. Price not applicable. Read SEC document |
| September 30, 2024 Filed Oct 1, 2024 20:51 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 21,190 | $0.00 | $0.00 |
DisclosureSEC source: 0001048477-24-000146 · wk-form4_1727815879.xml · nonDerivative · entry 1 Friberg Gregory R · CIK 0002038768 · EVP, Chief R&D Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,190 F1 · price: Restricted stock units granted on September 30, 2024. Price not applicable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.